A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Phase of Trial: Phase III/IV
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 05 Apr 2017 Trial design presented at the 108th Annual Meeting of the American Association for Cancer Research
- 22 Mar 2017 Planned number of patients changed from 1500 to 1000.
- 07 Oct 2016 Planned number of patients changed from 500 to 1500.